Summary
An advisory panel to the U.S. Food and Drug Administration will vote on whether Moderna’s mFlusiva influenza vaccine presents benefits that outweigh its risks for older adults. The panel meeting follows an agency reversal on an earlier rejection of Moderna’s application, and comes amid leadership turnover at the FDA and questions about trial design and certain population subgroups.
Regulatory context and approvals sought
Moderna has applied for two regulatory pathways for its seasonal flu candidate, branded mFlusiva: a traditional approval for adults aged 50 to 64, and an accelerated approval for adults 65 and older. Under the accelerated approval pathway, Moderna would be required to carry out additional studies to confirm clinical benefit in the older cohort. The company has agreed that if regulators grant approval for the 65-and-older group it will run an extra study and submit further data for that age range.
Timing and advisory committee process
The FDA’s Vaccine and Related Biological Products Advisory Committee will review briefing documents prepared by agency staff and then vote on the benefit-risk balance of the vaccine for older adults. The agency has indicated that a final decision on the application is expected by August 5.
Leadership changes at the FDA
The advisory meeting takes place after the departures of FDA Commissioner Marty Makary and the agency’s vaccine chief, Vinay Prasad. Their exits followed controversies surrounding reviews of vaccines and rare-disease drugs, including scrutiny of Moderna’s flu vaccine application. Senior FDA officials previously raised concerns that Moderna’s trial design may have put patients at risk by not using the preferred higher-dose flu vaccine as the control arm for participants aged 65 and over.
Acting Commissioner Kyle Diamantas has taken steps to stabilize agency operations and mend relationships with the biotechnology sector after a period of upheaval.
What the briefing documents say
FDA staff reviewers noted in briefing documents that data showing an immune response to Moderna’s mRNA flu shot could support effectiveness in adults aged 65 and older. At the same time, those documents highlighted concerns about performance in specific groups: immunocompromised individuals and very frail older adults were excluded from the trials, leaving uncertainty about how well the vaccine would work for those populations.
Moderna’s submission asserts that mFlusiva outperformed standard-dose influenza vaccines in adults 50 to 64. The company also referenced a separate, smaller study indicating a strong immune response compared with a high-dose influenza vaccine in adults 65 and older.
Expert comment
Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, noted the difference in evidence expectations for influenza products: "Every year when we approve flu vaccines, we don’t have efficacy data. So I think the question will be whether or not they thought that the immunogenicity study was big enough," he said.
Market implications and competition
If approved, mFlusiva would be the first seasonal influenza vaccine in the United States manufactured using mRNA technology. Moderna has emphasized that, unlike conventional flu vaccines, mFlusiva does not depend on chicken eggs for production. The company says this absence of an egg-based production step may allow manufacturers to better match the vaccine to circulating strains and shorten the interval between strain selection and vaccine availability.
The mRNA shot would enter a market that includes seasonal influenza vaccines from established manufacturers such as Sanofi, GSK, CSL Seqirus and AstraZeneca.
Commercial outlook cited in filings
Analyst Andrew Tsai at Jefferies has projected that Moderna is unlikely to record meaningful flu vaccine revenue until 2027. He estimated U.S. sales of combined flu and COVID-flu vaccines could reach roughly $750 million by 2030, according to materials included in public filings.
Next steps
The FDA advisory committee’s vote will be followed by an agency decision expected by August 5. Depending on the committee’s recommendation and the agency’s determination, Moderna may proceed with plans for broader rollout, or face additional data-generation requirements tied to accelerated approval for older adults.